Target intelligence / Profile preview

Pathogenic antigens recognized by pooled human immunoglobulin G

Molecular classification
Antigen, Protein, Polysaccharide, Glycoprotein, Lipopolysaccharide
01

Overview

Pathogenic antigens recognized by pooled human immunoglobulin G (IgG) encompass a vast array of molecular structures from bacteria, viruses, and other pathogens that are specifically bound by the Fab (fragment antigen-binding) regions of antibodies (StatPearls, 2023). These antigens include viral capsid proteins, bacterial surface polysaccharides, and exotoxins, such as those produced by Streptococcus pneumoniae or Clostridium tetani (NCBI, 2022). The interaction between the Fab regions of pooled IgG and these antigens is the primary mechanism for providing passive immunity in patients with primary or secondary immunodeficiencies. By binding to these targets, the antibodies neutralize viral infectivity, inhibit bacterial adherence to host tissues, and promote opsonization, which facilitates pathogen clearance by phagocytic cells (Journal of Clinical Immunology, 2018). Furthermore, pooled IgG contains antibodies that can neutralize superantigens, thereby preventing the massive, non-specific T-cell activation and cytokine release associated with certain severe infections (Frontiers in Immunology, 2020). This broad-spectrum recognition is achieved by pooling plasma from thousands of healthy donors, ensuring a diverse repertoire of antibody specificities.

Other names
Microbial antigensInfectious disease antigensIVIG-targeted antigensPathogen-associated molecular patterns recognized by IgG
02

Mechanism of action

The Fab regions of pooled IgG bind to specific epitopes on pathogenic antigens, leading to neutralization of toxins and viruses, inhibition of microbial attachment to host cells, and opsonization for phagocytosis by macrophages and neutrophils.

03

Biological functions

Immune responseNeutralizationOpsonizationPathogenesisHost-pathogen interaction
04

Disease associations

InfectionPrimary immunodeficiencySecondary immunodeficiencySepsisToxic shock syndrome
05

Safety considerations

Infusion-related reactions (e.g., headache, chills)Acute renal failure (particularly with sucrose-stabilized products)Thrombotic eventsAseptic meningitisHemolytic anemiaTransfusion-related acute lung injury (TRALI)
06

Interacting drugs

Intravenous immunoglobulin (IVIG)

2 more in the full profile.

07

Biomarkers

Serum IgG trough levelsSpecific antibody titers (e.g., anti-HBs, anti-pneumococcal IgG)B-cell counts

Beyond the preview

Go deeper on Pathogenic antigens recognized by pooled human immunoglobulin G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic antigens recognized by pooled human immunoglobulin G.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call